Hosted on MSN3mon
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
Sanofi SNY and Regeneron’s REGN Dupixent (dupilumab), an injectable monoclonal antibody that blocks IL-4/IL-13 signaling, is an approved therapy for multiple allergic and atopic diseases.
Too Old to Operate22h
Impact of Dupilumab on Skin Protein and Metabolite Composition in AD
The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...
pharmaphorum2y
Dupixent nears EU approval for rare skin disease prurigo nodularis
The EMA's human medicines committee (CHMP) has recommended IL-4 and IL-13 inhibitor Dupixent (dupilumab) to treat adults with moderate to severe PN, a disease which causes hard lumps to form on ...
psychiatryadvisor.com13d
In Atopic Dermatitis, Dupilumab Use Linked to Less Sleep, Psychiatric Disorders
Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.
Hosted on MSN2mon
Research shows dupilumab effective in treatment of children with atopic dermatitis
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities, Advances in Therapy (2024). DOI: 10.1007/s12325-024-02998-4 ...